カルナバイオサイエンスの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2017/06/21 | 1,700 | 1,704 | 1,660 | 1,702 | +2 | +0.1% | 125,700 |
| 2017/06/20 | 1,720 | 1,720 | 1,699 | 1,700 | -17 | -1% | 115,000 |
| 2017/06/19 | 1,700 | 1,733 | 1,700 | 1,717 | +7 | +0.4% | 85,200 |
| 2017/06/16 | 1,715 | 1,723 | 1,691 | 1,710 | +3 | +0.2% | 82,600 |
| 2017/06/15 | 1,720 | 1,743 | 1,701 | 1,707 | -26 | -1.5% | 120,400 |
| 2017/06/14 | 1,730 | 1,773 | 1,691 | 1,733 | +20 | +1.2% | 198,400 |
| 2017/06/13 | 1,717 | 1,737 | 1,680 | 1,713 | -1 | -0.1% | 117,400 |
| 2017/06/12 | 1,713 | 1,766 | 1,702 | 1,714 | +12 | +0.7% | 144,000 |
| 2017/06/09 | 1,709 | 1,714 | 1,690 | 1,702 | +21 | +1.2% | 75,600 |
| 2017/06/08 | 1,685 | 1,694 | 1,675 | 1,681 | -9 | -0.5% | 35,500 |
| 2017/06/07 | 1,682 | 1,692 | 1,677 | 1,690 | +8 | +0.5% | 42,900 |
| 2017/06/06 | 1,721 | 1,728 | 1,676 | 1,682 | -46 | -2.7% | 107,600 |
| 2017/06/05 | 1,731 | 1,741 | 1,718 | 1,728 | -11 | -0.6% | 40,000 |
| 2017/06/02 | 1,730 | 1,748 | 1,720 | 1,739 | +9 | +0.5% | 28,100 |
| 2017/06/01 | 1,720 | 1,734 | 1,718 | 1,730 | -3 | -0.2% | 32,800 |
| 2017/05/31 | 1,756 | 1,761 | 1,721 | 1,733 | -30 | -1.7% | 77,700 |
| 2017/05/30 | 1,758 | 1,780 | 1,742 | 1,763 | +5 | +0.3% | 62,200 |
| 2017/05/29 | 1,795 | 1,799 | 1,758 | 1,758 | -45 | -2.5% | 58,600 |
| 2017/05/26 | 1,807 | 1,808 | 1,790 | 1,803 | ±0 | ±0% | 30,600 |
| 2017/05/25 | 1,804 | 1,805 | 1,791 | 1,803 | -1 | -0.1% | 35,400 |
| 2017/05/24 | 1,782 | 1,807 | 1,777 | 1,804 | +17 | +1% | 27,700 |
| 2017/05/23 | 1,810 | 1,810 | 1,787 | 1,787 | -23 | -1.3% | 22,100 |
| 2017/05/22 | 1,800 | 1,815 | 1,786 | 1,810 | +20 | +1.1% | 42,700 |
| 2017/05/19 | 1,778 | 1,797 | 1,756 | 1,790 | +36 | +2.1% | 39,400 |
| 2017/05/18 | 1,744 | 1,809 | 1,744 | 1,754 | -30 | -1.7% | 55,100 |
| 2017/05/17 | 1,758 | 1,815 | 1,742 | 1,784 | +26 | +1.5% | 37,500 |
| 2017/05/16 | 1,744 | 1,760 | 1,741 | 1,758 | +15 | +0.9% | 29,500 |
| 2017/05/15 | 1,790 | 1,800 | 1,734 | 1,743 | -111 | -6% | 108,000 |
| 2017/05/12 | 1,804 | 1,854 | 1,793 | 1,854 | +58 | +3.2% | 50,100 |
| 2017/05/11 | 1,837 | 1,846 | 1,785 | 1,796 | -34 | -1.9% | 54,300 |
| 2017/05/10 | 1,840 | 1,845 | 1,824 | 1,830 | +6 | +0.3% | 28,400 |
| 2017/05/09 | 1,860 | 1,862 | 1,811 | 1,824 | -34 | -1.8% | 74,600 |
| 2017/05/08 | 1,785 | 1,858 | 1,784 | 1,858 | +89 | +5% | 92,500 |
| 2017/05/02 | 1,730 | 1,770 | 1,720 | 1,769 | +34 | +2% | 56,800 |
| 2017/05/01 | 1,711 | 1,737 | 1,700 | 1,735 | +24 | +1.4% | 46,300 |
| 2017/04/28 | 1,730 | 1,745 | 1,710 | 1,711 | -23 | -1.3% | 37,300 |
| 2017/04/27 | 1,736 | 1,751 | 1,720 | 1,734 | -1 | -0.1% | 46,200 |
| 2017/04/26 | 1,737 | 1,748 | 1,711 | 1,735 | +6 | +0.3% | 46,700 |
| 2017/04/25 | 1,711 | 1,742 | 1,704 | 1,729 | +19 | +1.1% | 33,700 |
| 2017/04/24 | 1,795 | 1,795 | 1,704 | 1,710 | -92 | -5.1% | 81,800 |
| 2017/04/21 | 1,759 | 1,804 | 1,732 | 1,802 | +65 | +3.7% | 58,800 |
| 2017/04/20 | 1,754 | 1,759 | 1,719 | 1,737 | -17 | -1% | 32,800 |
| 2017/04/19 | 1,725 | 1,780 | 1,710 | 1,754 | +16 | +0.9% | 35,200 |
| 2017/04/18 | 1,700 | 1,742 | 1,683 | 1,738 | +55 | +3.3% | 53,200 |
| 2017/04/17 | 1,616 | 1,687 | 1,616 | 1,683 | +27 | +1.6% | 52,300 |
| 2017/04/14 | 1,682 | 1,710 | 1,655 | 1,656 | -61 | -3.6% | 93,100 |
| 2017/04/13 | 1,641 | 1,728 | 1,641 | 1,717 | +28 | +1.7% | 71,400 |
| 2017/04/12 | 1,791 | 1,792 | 1,689 | 1,689 | -130 | -7.1% | 154,900 |
| 2017/04/11 | 1,770 | 1,829 | 1,770 | 1,819 | +43 | +2.4% | 46,200 |
| 2017/04/10 | 1,810 | 1,825 | 1,770 | 1,776 | -34 | -1.9% | 55,900 |
1801～
1850
件表示中 / 3572件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| カルナバイオ | 30,400円 | -43.1% | - | 0.00% | - | 1.81倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
| カイオム | 9,900円 | +2.6% | - | 0.00% | - | 5.73倍 |
|
独自の抗体作製技術を持つ理研発の創薬ベンチャー。医薬品候補抗体導出と技術供与が収益源 |
| ＶＩＳ | 91,000円 | +87.8% | +265.7% | 0.00% | 54.65倍 | 2.51倍 |
|
ｍＲＮＡ標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
| クリングル | 82,300円 | +14.5% | - | 0.00% | - | 2.43倍 |
|
細胞の増殖、保護、修復などの機能があるＨＧＦタンパク質を用いて、難治性疾患治療薬を開発 |
| ＤＥＬＴＡ－Ｐ | 65,800円 | - | - | 0.00% | - | 4.40倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
市場注目の銘柄
チャート関連のコラム
